The aim of this study is to evaluate the efficacy of stereotactic radiotherapy boost (SRB) in patients with glioblastoma multiforme (GBM) by comparing two different regimens, single dose or fractionated treatment. Between December 1994 and January 2000, 24 patients with GBM were treated with SRB in conjunction with external beam radiotherapy (EBRT).
Introduction
Surgery, conventional external radiotherapy, and chemotherapy can prolong survival in patients with GBM, although the prognosis remains poor, with few longterm survivals (1). In the majority of patients, tumors eventually recur locally after initial treatment (2). Local control is critical to improve the survival of patients with GBM, since most patients die of progressive disease at or in close proximity to the original site of the tumor (2,3).
A dose-response relationship has been found in the treatment of GBM with conventional EBRT of up to 60 Gy delivered in a conventional fractionation scheme (4). Potential detrimental effects, however, have been suggested when EBRT was given beyond 60 . Since most failures occur locally for GBM after treatment, various methods have been explored to allow radiation dose escalation by incorporating brachytherapy (8-10) or stereotactic radiosurgery (11) (12) (13) (14) (15) (16) in an attempt to improve local control. These reports suggested improved survival with dose escalation with a boost after EBRT. However, three recent randomized studies (17) (18) (19) , two brachytherapy boost and one stereotactic boost studies did not demonstrate survival advantage in GBM patients (non-GBM patients included in both brachytherapy trials). Due to the fact that there is a high rate of local recurrence even after initial treatment (2), it is still reasonable to consider giving a local boost to enhance the local control.
Stereotactic radiosurgery has been administered in a single high-dose fraction, even though a fractionated regimen is known to be radiobiologically advantageous particularly in patients with malignant tumors. No attempt has been made in SRS to spare normal cells within the irradiated volume by dividing the total tumor dose into a number of fractions. The rationale for this practice is that when the treatment volume is small and contains little functioning brain tissue, the need for fractionation may not apply. However, a single fractional highdose treatment becomes a concern because of potential morbidity when the tumor volume becomes large (usually > 4 cm in diameter) or the tumor is in or close to eloquent structures (e.g., optic pathway, basal ganglia, speech or motor area, etc.). For this reason, from 1993 onward, the University of Minnesota has utilized FSRT to primarily treat patients with malignant gliomas who are not appropriate for SRS due to either size or location of tumor. This retrospective study is to evaluate the efficacy of stereotactic radiotherapy boost (SRB) as part of initial treatment in patients with GBM by comparing two different regimens, single dose or fractionated stereotactic radiotherapy.
Methods and Materials

Patient Selection
Between April 1994 and January 2000, 24 patients with GBM were treated with SRB in conjunction with EBRT at the University of Minnesota Hospital using a 6 MV linear accelerator. Before treatment, the histologic diagnosis was confirmed at our institution by review of the original pathologic material. Tumor grade was scored by the World Health Organization's (WHO) grading system (20) . All the pathology slides were read by one neuropathologist. All twenty four patients had grade 4 astrocytoma with spontaneous tumor necrosis (GBM) on pathologic specimen. Fourteen patients were male and ten were female. Median age was 52 years (range, 14-80 years). All patients had a KPS of > 60%, with a median of 70% (range, 60-90). The location of tumors included 6 (25%) frontal, 9 (38%) temporal, 5 (21%) parietal, 1 (4%) occipital, 1 (4%) corpus callosum, and 2 (8%) basal ganglia. A recursive partitioning analysis by the RTOG of malignant glioma trials has stratified malignant glioma patients into 6 prognostically significant classes (21). We used the RTOG criteria to analyze our data. All patients had the data (e.g., age, KPS, tumor histology, etc.) making them eligible for stratification into the RTOG prognostic classes. Our patients were categorized in the RTOG Classes 4 (11 patients), 5 (10 patients), and 6 (3 patients). Table I summarizes patients' characteristics.
Fourteen patients (58%) underwent at least partial surgical resection and 10 (42%) underwent a stereotactic biopsy. All patients had conventional EBRT, with a median dose of 60 Gy (range, delivered in a median number of 30 fractions (range, 27-33 fractions). The initial 45-46 Gy were delivered to a generous area including enhancing tumor, peritumoral edema with a 2 centimeter margin. Additional external beam boosts were given to the enhancing tumor plus 2-3 cm margin to bring the total dose up to 50.4-60 Gy. Adjuvant chemotherapy was administered to 27 patients (83%).
Patients were considered for SRS or FSRT boost if the Karnofsky Performance Status (KPS) was 60 or above, the tumor size was no more larger than 5 cm, the tumor was not less than 0.5 cm from the optic apparatus (the total dose to the optic apparatus was limited to 54 Gy or lower), the tumor was not abutting the brainstem, and the shape of the tumor was either spherical or elliptical. SRS was delivered to 14 patients (65%) and FSRT to 10 patients (35%). Median interval between EBRT and SRB was 1.4 months (range, -0.4 to 3.9 months). Among 14 patients treated with SRS, 6 patients received up-front SRB prior to EBRT and the remaining 8 patients received SRB after EBRT. All ten patients treated with FSRT had SRB after EBRT. Among 10 patients treated with FSRT, fractionated treatment was selected because of larger tumor size (> 4 cm) in 7 patients or tumor located close to or at the eloquent structures in 3 patients (one had tumor in the speech area, 1 in the motor area, and 1 in the basal ganglia). Treatment is summarized in Table II .
Stereotactic Radiotherapy Technique
The technique for single fraction high-dose SRS was described in detail in our previous publication (22) . Briefly, the Brown-Roberts-Wells stereotactic frame (Radionics, Inc., Burlington, MA) was applied with local anesthesia for head fixation during CT scanning and at the time of treatment. The head was scanned in 4 mm sections outside the target and with either 1 mm or 2 mm sections through the target. Treatment planning was performed with the X-Knife Stereotactic Radiosurgery System (Radionics Software Applications, Inc., Burlington, MA). The target and doselimiting structures, such as the eyes, optic nerves, optic chiasm, and brain stem, were delineated on CT. The stereotactic boost target was defined as the contrast-enhancing tumor on CT. Treatment planning to determine the treatment isodose, maximum dose, and dose to the enhancing margin of the tumor was performed by the radiation oncologist, neurosurgeon, and radiation physicist. The number of isocenters, collimator sizes, and number of arcs and degrees of gantry rotation were chosen to optimize the radiation dose to the target and to minimize the dose to the adjacent normal brain parenchyma. The minimum peripheral dose (MPD) encompassing the target was chosen to prescribe the dose to the tar-get. This prescription dose was normalized to the maximum dose within the treatment volume. Median MPD was 10.5 Gy (range, 10-18 Gy) for patients treated with SRS. This was prescribed to a median of 86% (range, 50%-90%) IDS encompassing the target. The planning system included algorithms to calculate the treatment volume, to which the chosen MPD was delivered to completely encompass the enhancing tumor. Consequently, the treatment volume was defined as the tissue volume within the IDS to which the MPD was prescribed. Tumor-volume ratio (TVR) was also calculated by a formula, treatment volume divided by tumor volume. The median tumor volume, treatment volume and TVR (range) for patients treated with SRS were 27 ml (9-57), 64 ml (24-132), and 2.3 (1.7-2.8), respectively (Table II) .
The technique of FSRT has been described in detail elsewhere (23). The treatment planning process for FSRT and SRS was identical with the exception of the head frame used. For FSRT, the Gill-Thomas-Cosman relocatable head frame (Radionics Inc. Burlington, MA) was used for planning and treatment. This head frame can reproduce patient head position with a custom-fitted dental plate and an occipital mold for fractionated treatment. The delivery of conformal treatment using arc therapy is often very difficult for larger non-spherical targets (e.g., most of the larger gliomas) because of an increase in the volume of normal brain within the treatment volume. In these cases, static beam(s) in combination with arc therapy was used to achieve more conformal delivery of radiation to the target whenever possible. For the FSRT group, the median dose of 27.5 Gy (range, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was delivered in a median number of 11 fractions (range, 8 -14 fractions) to a median IDS of 88% (range, 75%-90%). A relatively smaller fractionated dose (compared to hypofractionated treatment) with a median of 2.5 Gy per fraction (range, 1.8 Gy-3 Gy/fraction) was given daily, five times a week (i.e., 8 patients were treated with a fractional dose of 2.5 Gy, 1 patient with 1.8 Gy, and 1 patient with 3 Gy). The median tumor volume, treatment volume, and TVR (range) for patients treated with FSRT were 34 ml (4-70), 71 ml (11 -195) , and 2.8 (1.9-2.9), respectively (Table II) .
Post-treatment Evaluation
After treatment, patients were followed with serial neurological and radiological examinations. Follow-up CT scans or magnetic resonance imaging (MRI) were obtained routinely at three month intervals, or in the event of an unexpected neurological worsening. These scans were reviewed by the members of the radiosurgical team to assess the therapeutic response. Indication for a reoperation after SRS or FSRT was clinical and radiographic progression with substantial mass effect that was refractory to corticosteroid therapy. Indication for reoperation was not strictly followed and the decision to perform reoperation was made individually based on lesion location and expected morbidity from surgical resection. Patients who lived at a distance from Minneapolis were monitored by telephone with the assistance of the patient's primary physician or oncologist.
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Statistical Analysis
Actuarial survival was calculated from the date of initial surgery or biopsy using the Kaplan-Meier method. Univariate comparisons of survival between different groups were performed using the log-rank test. Variables that were compared included gender (male vs. female), the RTOG classes (4 vs. 5 vs. 6), extent of surgery (biopsy only vs. resection), SRB modality (SRS vs. FSRT), and reoperation after SRB (yes vs. no). For variables that were continuous, including age, KPS, the RTOG classes, tumor volume, and treatment volume, univariate and multivariate analyses were also performed using a Cox multiple regression method to identify variables that influenced outcome. The log-rank test was performed to compare the risk of complications between SRS and FSRT.
Results
Survival and Prognostic Variables Predicting Longer Survival
All 24 patients were included in the overall survival analysis. Actuarial survival rates were 63% at one year and 34% at two years, with a median of 16 months (range, 3.9-53.9 months) from the time of surgery or biopsy ( Figure 1 ).
Median follow-up period was 12.1 months (range, 3.9-53.9 months). At the time of analysis, 8 patients (33%) were alive 3.9 to 53.9 months (range) from the time of treatment. Actuarial median survival time was 16 months (range, 5.9-53.9 months) for the SRS group and 15.9 months (range, 3.9-52.8 months) for the FSRT group (p=0.8, log-rank) (Table III, Figure 2 ). A univariate comparison of survival between groups is shown in Table III and Figure 3 . Among the variables compared, the RTOG classes ( Figure 3A ; p = 0.02), extent of surgery ( Figure 3B ; p = 0.004) and reoperation ( Figure 3C ; p = 0.02) were predictive of survival. Gender (male vs. female), and SRB modality (SRS vs. FSRT) did (Table IV) . Among these variables, only age was statistically significant by multivariate analysis (p = 0.04). Neither the tumor volume nor the treatment volume significantly influenced outcome.
Patterns of Failure
A local failure was defined as a contiguous progression of contrast enhancement beyond the SRB volume. A regional failure was defined as a noncontiguous recurrence of the tumor outside the SRB volume, which included new parenchymal disease or leptomeningeal metastases. Based on these criteria, 15 of 24 patients (63%) had progressive disease within the brain. Nine patients were excluded from analysis of patterns of failure. Three of these patients died of intercurrent disease (one died of massive pulmonary embolism, one died of pneumonia, and one died of cerebral vascular accident), and the remaining six patients were alive with no evidence of progressive disease in the brain at the time of analysis. Among these 15 patients, 7 (47%) had local progression and 8 (53%) had regional progression. Of the patients with regional failure, 7 patients (47%) had new parenchymal disease outside the SRB volume and one patient (7%) had leptomeningeal disease (Table V) .
Complications
The perioperative morbidity was minimal and no mortality related to the radiosurgical procedure was observed. No major bleeding or infection was observed at the insertion sites where the scalp pins were attached to the skull. Most patients treated with FSRT tolerated well the daily placement of the relocatable head frame, although a few patients complained of a sore mouth from the tight dental impression. Anticonvulsants were not routinely prescribed to patients unless they had a history of seizures or had a cortical lesion. Patients were not routinely placed on corticosteroids unless they had significant vasogenic edema with mass effect on surrounding tissue. About one-half of the patients (14 patients) were on corticosteroids before SRT. In 12 patients (50%), initiation or increased dosage of corticosteroid therapy was required for the transient progression of neurologic symptoms, presumably due to radiationinduced swelling of irradiated tissue (Table VI) .
Late complications (more than one month after SRT) were attributed to radiation necrosis within the treatment volume. Eight of the 24 patients (33%) (6 in SRS group and 2 in FSRT group) underwent a reoperation for radiographic and/or symptomatic progression with a mass effect that did not respond well to corticosteroid therapy. Among the 6 patients in the SRS group, 2 patients had recurrent tumor, 2 had brain necrosis without viable tumor cells, and the remaining 2 had a mixture of tumor and necrosis on pathologic specimen. Of two patients in the FSRT group undergoing a reoperation, one had persistent tumor without necrosis and one had a mixture of tumor and necrosis. The prevalence of these complications were more common in SRS group, but these were not statistically different between the two treatment groups probably due to small sample size (Table VI) .
Discussion
Survival
Local control is critical to improve the survival of patients with high-grade gliomas, since most patients die of progressive disease at or in close proximity to the original site of tumor (2, 3) . A dose-response relationship has been found in the treatment of malignant gliomas with EBRT of up to 60 Gy delivered in a conventional fractionation scheme (4). However, a recent RTOG study using a hyperfractionated regimen of 72 Gy (1.2 Gy per fraction, twice a day, five days a week) failed to show any benefits over conventionally fractionated regimen of 60 Gy (2 Gy per fraction, once a day, five days a week) (6). The outcome of conventionally fractionated regimen was in fact superior to hyperfractionated regimen for a subgroup of patients under age 50. This suggests that dose escalation beyond 60 Gy delivered in conventional external beam techniques does not improve the therapeutic ratio. Although the RTOG study gave no explanation as to why the hyperfractionated regimen with a higher total dose did not improve outcome, it might be related to the fractionation scheme, treatment related toxicities, and/or treatment techniques. There are numerous studies in which brachytherapy within a welldefined target has been used as part of the initial management of gliomas (8-10). The increased survival found in these studies was associated with a brachytherapy boost in conjunction with EBRT, contrary to the external beam experience. Although the increased survival associated with brachytherapy may in part reflect the selection bias associated with choosing prognostically favorable candidates for the procedure, patients with GBM treated with a brachytherapy boost had a median survival time of 18 months compared with 11 months for a control group with similar clinical and radiographic features (10). Furthermore, a dose-response relationship was found between a minimum brachytherapy tumor dose and survival (and local control) (9). Two recent randomized trials did not support the use of brachytherapy as a boost after EBRT (17, 18) . In both trials, patients with non-GBM malignant gliomas were included and the patients were not stratified according to the RPA classes. Furthermore, in the Canadian study, though not statistically significant, there was a trend toward a relative risk of 0.7 (P = 0.07) with the use of brachytherapy as a boost (17). This might be related to the small sample size.
Previously demonstrated improved outcomes with brachytherapy provided the rationale for treating malignant gliomas with stereotactic radiosurgery. Several studies have evaluated the efficacy of radiosurgical boost as part of initial therapy in patients with malignant gliomas and demonstrated survival improvement with median survival time ranging from 9.5 to 20 months (11) (12) (13) (14) (15) (16) . In one study, the median survival time from diagnosis was 19.5 months in 49 patients with GBM treated up front with radiosurgery *Patterns of failure = A local failure was defined as a contiguous progression of contrast enhancement beyond the SRB volume; a regional failure was defined as a noncontiguous recurrence of the tumor outside the SRB volume, which included new parenchymal disease or leptomeningeal metastases. † Number of Patients = Nine patients were excluded from analysis of patterns of failure; six patients were alive with no evidence of progressive disease in the brain at the time of analysis and three died of intercurrent disease before follow-up imaging studies. (24). Another analysis in which brachytherapy and stereotactic radiosurgery were compared with a control group treated with EBRT among prognostically comparable patients with GBM (matched for age, performance status, and presence of radiographically well-defined tumors) showed a significant enhancement of survival for both the brachytherapy and radiosurgery patients when compared with the control group (25). Thus, technique appears to be critical to improve the therapeutic ratio and a boost, in conjunction with 60 Gy of EBRT, should be delivered by conformal techniques such as interstitial brachytherapy or stereotactic radiotherapy. However, the results of a phase III randomized study from RTOG reported recently did not support the use of SRS boost for GBM (19) . However, in the study, the pattern of failure was mainly local (more than 90% of the patients presenting with a component of local failure). Furthermore, the median survival reported for the patients of RPA class III/IV in the trial was on the range of 14-15 months, which was much shorter than the RPA class IV patients in our series. Data from University of Michigan dose escalation study with three dimensional conformal radiation therapy to a dose of 90 Gy showed that despite the dose escalation, the main pattern of failure was still local (26). In our series, while 30% of patients (n = 7) developed local progression, 33% of the patients (n = 8) developed regional progression outside the high dose zone. Even with apparently enhanced local control, regional failure still represents a major problem.
The choice of dose-fractionation parameters, equivalent to single fractional dose, is not defined. The dose of 2.5 Gy per fraction was chosen as a compromise between protracted treatment with conventional fractionation (< 2 Gy) and hypofractionated treatment (usually > 5 Gy in the literature) (27) (28) (29) . Hypofractionation with fewer large fractions may shorten overall treatment time, but may compromise too much of the potential advantages of fractionation. We thought that 2.5 Gy per fraction appears reasonable without compromising the potential advantages of fractionation too much. Preliminary data demonstrated median dose of 10.5 Gy delivered in patients treated with single dose of SRS as a boost. When we started FSRT, we tried to find the equivalent total dose in 2.5 Gy/fraction. It was decided to administer a total of 27.5 Gy in 11 fractions for 2.2 weeks, which is approximately equivalent to 10.5 Gy in a single fraction for late-responding tissue (alpha-beta ratio = 2 Gy; and to 14 Gy in single fraction for early-responding tissue (alpha-beta ratio = 10 Gy) when a linear quadratic model is presumed to represent the cell survival curve following radiation (30).
Many confounding factors influence the survival of patients with GBM and the relative impact of different fractionation scheme (SRS vs. FSRT) is difficult to discern in this retrospective analysis. The pre-existing prognostic variables are not well balanced between the two treatment groups (SRS vs. FSRT) by selection bias. SRB modality (SRS vs. FSRT) did not significantly influence survival with median survival time of 16.0 months for patients treated with SRS and 15.9 months for those treated with FSRT. Tumor size is known to adversely affect the longevity of patients with high-grade gliomas (31). By selecting FSRT as a treatment modality for larger tumors, the target and treatment volumes were larger for FSRT treated patients, compared to those treated with SRS. Although patients treated with FSRT had potentially more unfavorable prognostic variables, the outcome was similar between the two treatment groups with median survival time of 16 months for the SRS group and 15.9 months for the FSRT group. The overall acute and late complication rates appeared to be higher in the SRS treated patients compared to those treated with FSRT; which was not, however, statistically significant probably due to small sample size.
Prognostic Variables
Among variables analyzed by the univariate log-rank test, the RTOG class, extent of surgery and reoperation following SRB were predictive of survival. In the present study, the median survival times for the RTOG 4, 5, and 6 were 28.3, 10.3, and 6.0 months following EBRT and SRB, respectively. Based on the RTOG recursive partitioning analysis in patients with malignant gliomas (9), the expected median survival times for the RTOG class 4, 5, and 6 are 11.1, 8.9, and 4.6 months following EBRT, respectively. Compared to the RTOG database, median survival achieved by the addition of SRB is improved most demonstrably for the RTOG class 4, 28.3 months with EBRT + SRB vs. 11.1 months with EBRT alone. Although a statistical analysis was not possible to validate whether the improvement of survival is due to therapeutic effects of SRB or due to selection bias in this retrospective analysis, it appears that SRB is particularly beneficial to those of the RTOG class 4 who have relatively favorable prognostic features such as younger age (< 50), higher KPS (> 70), and tumor resected at least in part while maintaining their neurological functional status fitted for active work (see also reference 32 to understand clinical characteristics of patients in the RTOG class 4).
Whether the extent of surgery has any impact on survival in patients with GBM has been a controversial issue. Some authors demonstrated a beneficial effect of debulking surgery (6, 14, (33) (34) (35) and some did not (36) (37) (38) . In the present study, surgical resection appeared to prolong survival, when compared to biopsy only. Evidence indicates that a reoperation has an impact on survival when tumor recurs after initial treatment (32, 39, 40) . One study found longer survival in patients undergoing a reoperation after brachytherapy or SRS for GBM compared with similar patients not undergoing a reoperation (41). We also previously reported the potential beneficial effect of reoperation following stereotactic radio-therapy for patients with recurrent malignant gliomas (42). In the present study, patients undergoing a reoperation after SRT also showed longer median survival compared with patients who did not (25.1 vs. 10.9 months), which was statistically significant (p = 0.02 by log-rank test). Longer survival in patients undergoing a reoperation was likely due to either therapeutic effects of reoperation in terms of tumor control, or selection bias in which reoperation was selected for favorable patients. This would include patients whose tumors, after initially responding well to radiation, became necrotic and caused greater mass effect that subsequently required a reoperation. In addition, it is possible that patients undergoing reoperation were medically more fit for surgery/anesthesia and their tumors were more favorable in size and location. In these patients, reoperation was possible without serious postoperative morbidity. In our retrospective analysis it was difficult to determine whether longer survival in patients undergoing reoperation is a result of therapeutic effect of the procedure or of selection bias. What is obvious from our analysis , however, is reoperation is a necessary component of treatment in a fraction of patients following SRT. Reoperation does not necessarily adversely affect the overall outcome and is required more often after SRS than FSRT.
For continuous variables, younger age, higher KPS, and lower RTOG class predicted longer survival by univariate analysis (Table IV) . Among these variables, age was the only variable which was statistically significant by multivariate analysis. Age, KPS, and tumor grade are common independent variables predicting the longevity of patients with high-grade gliomas (4-7, 18, 41, 42) . The impact of tumor size on outcome is less clear, however. In the present study, smaller tumor volume did not predict longer survival by univariate analysis. Treatment volume, which is dependent on the volume of target, was not found statistically significant by univariate analysis.
Conclusion
Our retrospective data suggest that SRB in conjunction with EBRT may improve survival in patients with GBM with median survival of 16 months, which is longer than the historical data in the literature which is typically 10-12 months following EBRT. Compared to the RTOG database, median survival achieved by the addition of SRB appeared to improve most demonstrably for the RTOG class 4. Despite the presence of worse prognostic factors for patients in the FSRT group, SRS and FSRT are equally effective with similar median survival. The overall acute and late complication rates appeared to be higher in the SRS treated patients compared to those treated with FSRT, which was not, however, statistically significant probably due to small sample size. Since this is a retrospective study with small sample size, further investigation is needed to confirm this and to determine an optimal dose/fractionation scheme. While SRB may improve local control, regional failure represents a major challenge. Additional innovative treatments are to be explored to improve treatment outcome. 
